Mindray Acquires Majority Stake in DiaSys Diagnostic Systems GmbH
Mindray Has Agreed to Acquire 75% Stake in Germany-Based DiaSys Diagnostic Systems GmbH
Mahwah, NJ – July 31, 2023 – Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ( “Mindray”) has agreed to acquire 75% equity interest in DiaSys Diagnostic Systems GmbH (“DiaSys”) from Gorka Holding GmbH, through Mindray Medical Netherlands B.V. (“Mindray Netherlands”), a wholly-owned subsidiary of Mindray’s wholly-owned subsidiary MR Global (HK) Limited, for an all-cash preliminary purchase price of approx. €115 million. The final purchase price will be determined as of closing. Upon completion of the proposed transaction, Mindray will hold 75% equity interest in DiaSys and consolidate DiaSys and its subsidiaries. Upon closing, Mindray Netherlands and Gorka Holding GmbH will proportionally contribute €40 million to DiaSys, which will be used to support DiaSys’ future business development.
Established in 1991 and headquartered in Holzheim, Germany, DiaSys is a globally recognized brand with over three decades of expertise in the fields of in vitro diagnostics (“IVD”). DiaSys has production facilities across Europe, APAC, and Latin America.
“We are very pleased to see this collaboration come to fruition, as Mindray’s and DiaSys’ businesses strongly complement each other. Through this acquisition, Mindray will effectively improve its overseas supply chain platform and support the penetration of our IVD business in the medium to large customer segments. We look forward to both parties jointly realizing synergies and creating greater value for our customers,” said Wu Hao, President of Mindray
Going forward, Mindray will leverage DiaSys’ global supply platforms and international team of professionals to expedite overseas supply chain construction, in order to achieve the further expansion into medium to large volume customer segments worldwide, and offer more timely and comprehensive professional service to clients.
At the same time, DiaSys’ extensive experience in clinical chemistry is also expected to bring synergies to Mindray’s IVD business. DiaSys’s ability to develop and produce IVD controls and calibrators will complement Mindray’s IVD product offering and enhance its system performance.
“DiaSys with its comprehensive range of products and global manufacturing footprints, and Mindray with its total IVD solutions and worldwide network, are ideal partners for lifting synergies in the IVD field. The individual strengths of both partners will support each other and help for a common and sustainable success in all regions of the world,” adds DiaSys’ Founder, Dr. Günther Gorka.
Closing of the proposed transaction is subject to customary regulatory approval as well as satisfaction of certain conditions agreed by the parties.
Mindray is a leading developer, manufacturer, and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of life-saving tools across three primary business segments: patient monitoring and life support, in-vitro diagnostics, and medical imaging. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in Silicon Valley, with additional facilities in major international markets around the world.
DiaSys is a leading specialist in the development and manufacturing of diagnostic system solutions of highest quality, trusted by customers in more than 140 countries for over 30 years. Its product portfolio comprises more than 90 clinical chemistry and immunoturbidimetric reagents for routine and special diagnostics including suitable calibrators and controls as well as instrumentation products.